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Abstract: Yellow fever virus (YFV) is a mosquito-borne member of the genus flavivirus, including
other important human-pathogenic viruses, such as dengue, Japanese encephalitis, and Zika. Herein,
we report identifying 129 YFV Class II epitopes in donors vaccinated with the live attenuated YFV
vaccine (YFV-17D). A total of 1156 peptides predicted to bind 17 different common HLA-DRB1 allelic
variants were tested using IFNγ ELISPOT assays in vitro re-stimulated peripheral blood mononuclear
cells from twenty-six vaccinees. Overall, we detected responses against 215 YFV epitopes. We found
that the capsid and envelope proteins, as well as the non-structural (NS) proteins NS3 and NS5,
were the most targeted proteins by CD4+ T cells from YF-VAX vaccinated donors. In addition,
we designed and validated by flow cytometry a CD4+ mega pool (MP) composed of structural
and non-structural epitopes in an independent cohort of vaccinated donors. Overall, this study
provides a comprehensive prediction and validation of YFV epitopes in a cohort of YF-17D vaccinated
individuals. With the design of a CD4 epitope MP, we further provide a useful tool to detect ex vivo
responses of YFV-specific CD4 T cells in small sample volumes.
Keywords: yellow fever virus; epitopes; CD4+ T cells; vaccination; T cells
1. Introduction
Yellow fever (YF) is a mosquito-borne acute viral disease, currently endemic to the tropical and
subtropical regions of Africa and the Americas. Although many people do not experience symptoms,
the most severe cases include acute fever, organ failure, jaundice, dark urine, abdominal pain, and even
death [1]. YF is caused by the yellow fever virus (YFV), an RNA virus from the flavivirus genus, which is
closely related to the dengue, Japanese encephalitis, Zika, and tick-borne encephalitis viruses [2].
The Aedes or Haemagogus species of mosquitoes, are responsible for YFV transmission through sylvatic,
intermediate, and urban cycles, affecting both human and non-human primates. Before introducing
large-scale vaccination, the impact of YF epidemics on human health, especially amongst children and
the elderly, was staggering [3]. Development of the live attenuated YF-17D based vaccines (17D-204
and 17DD) in the late 1930s and subsequent large-scale immunization programs, led to the control
and virtual elimination of urban epidemics. The yellow fever 17D-based vaccine (YF-17D) is a live
attenuated vaccine produced by Sanofi Pasteur under the tradename YF-VAX®and is the only YF
vaccine licensed in the United States [4].
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Vaccination is an important strategy to combat flaviviral diseases, and the YF vaccine is amongst
the most successful vaccines ever produced [5]. A single dose of the YF vaccine elicits neutralizing
antibodies in vaccinated individuals for 30 or more years, and may provide lifelong immunity [6].
Several studies have reported class II and class I restricted epitopes [7–19], but a systematic analysis
providing comprehensive coverage of common HLA types has not been reported. The interest of such
an analysis is several-fold.
First, T cell responses are an essential component of the immune responses elicited YFV. However,
in contrast to multiple system biology studies that analyzed correlates of protection at the level of
antibody responses [6,20,21], T cell responses as potential correlates of the protection and immunity
elicited YFV vaccination are not fully understood [22], despite circumstantial evidence that suggests that
T cell responses are important for immunity to flaviviruses in general and to YFV in particular [22–24].
Second, a detailed assessment of T cell responses to YF in the natural setting, is also important
in the context of potential disease outbreaks, to define natural disease, potential immunopathology,
and host-virus interactions. These are pressing concerns because, despite the success and efficacy of the
YF-17D vaccine, the World Health Organization in 2018 reported major YF outbreaks in five countries
(Brazil, Congo, Ethiopia, Nigeria, and South Sudan), cases with epidemic potential were informed from
the Democratic Republic of the Congo, and signals of disease activity were reported in Central African
Republic, Guinea, Liberia, Bolivia, Colombia, French Guiana, and Peru [1]. Due to multiple factors,
such as low vaccination coverage against YFV in individuals living in endemic areas, the presence of
non-human wildlife reservoirs, and the climate change-related expansion of suitable endemic areas in
previously non-endemic regions, there is a high probability of future YF epidemics [25–27].
Third, it is important to be able to characterize YF-induced T cell responses, to be able to assess
whether these responses are cross-reactive with other flaviviruses, and because YF backbones are used
as a vaccine delivery vector [24]. Considering different flaviviruses species, little cross-reactivity exists
at the level of antibody responses that target mostly the E protein, while T cell responses are known
to target Non-structural (NS) proteins, which are more conserved, raising the possibility that T cell
responses might be more cross-reactive. Whether cross-reactive T cell responses can alter or influence
the outcome of infection with other related flaviviruses is currently undetermined. It is also important
to assess cross-reactivity in light of the fact that YFV is also utilized as a carrier for delivery of antigens
from other pathogens, as illustrated by the DENGVAXIA vaccine, which utilizes a YFV backbone to
deliver pre-membrane (prM) and envelope (E) proteins from the four serotypes of dengue virus [28].
The use of YF vaccination to induce or recall responses against specific epitopes is, therefore, of interest
from various perspectives.
In the present study, we analyzed the human CD4+ T cell responses and associated epitope
repertoires restricted by HLA class II in vaccinated individuals. Peptides restricted by 17 HLA
Class II DRB1 alleles were synthesized and tested for their capacity to recall T cell responses from
peripheral blood mononuclear cells (PBMCs) derived from HLA-matched donors that received the YF
vaccine. Based on the results of this epitope identification screen, we designed and validated a pool of
YF-derived CD4 epitopes that allows the ex vivo detection of vaccine-induced CD4+ T cell responses
in small sample volumes, irrespective of HLA phenotype.
2. Materials and Methods
2.1. Human Blood Samples from Vaccinated Individuals
For the epitope identification studies, twenty-six peripheral blood samples were obtained from
local adult blood donors from the San Diego area in an anonymous fashion. Donors previously
vaccinated with YF-VAX included in the present study, were of both genders, and aged between 18
and 59 years old. Samples were collected over 40 months, between April 2015 and August 2018. The
characteristics of this study population are summarized in Table S1.
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To confirm the identified epitopes and the mega pool validation, we utilized 15 peripheral blood
samples from previously YFV vaccinated volunteers obtained from local adult blood donors from
the San Diego area in an anonymous fashion. Moreover, in this cohort, both sexes were represented,
and donors ranged from 18 to 60 years of age. Details of this donor cohort are shown in Table S2.
All donors utilized in this study have been collected in the greater San Diego area where neither
dengue, Japan encephalitis, or Zika viruses are endemic. However, we cannot exclude that any
of the study participants have traveled to endemic areas and could, thus, have been exposed to
other flaviviruses.
Peripheral blood mononuclear cells (PBMCs) were purified by density gradient centrifugation
(Ficoll-Paque Premium; GE Healthcare Biosciences) resuspended in fetal bovine serum (Gemini
Bio-products, Sacramento, CA) containing 10% dimethyl sulfoxide (DMSO), and subsequently
cryopreserved in liquid nitrogen. Institutional Review Board (IRB) of La Jolla Institute for Immunology
approved all protocols described in the present study (VD-101).
2.2. HLA Typing
Donors for the epitope identification studies were HLA typed by an ASHI-accredited laboratory
at Murdoch University (Western Australia) using locus-specific PCR amplification on genomic DNA as
previously described [29]. Donors and their corresponding HLA phenotype are listed in Table S1.
2.3. MHC Class II Binding Predictions and Peptide Selection
A panel of 681 15-mer peptides overlapping by 10 residues and spanning the entirety of the
YF-17D polyprotein was synthesized (Mimotopes, Victoria, Australia) on a small scale as crude material.
Each peptide was then submitted for analysis to identify the top 10% (n = 68) scoring peptides for each
HLA class II considered. HLA-DRB1 binding predictions were performed using the Immune Epitope
Database (IEDB), and Analysis Resource (www.iedb.org; [30]) recommended methods, as of July
2016 [31–33]. A panel of 17 HLA-DRB1 alleles was considered, to include, DRB1*01:01, DRB1*03:01,
DRB1*04:01, DRB1*04:03, DRB1*04:05, DRB1*04:07, DRB1*07:01, DRB1*08:02, DRB1*10:01, DRB1*11:01,
DRB1*11:04, DRB1*12:01, DRB1*13:01, DRB1*15:01, DRB1*15:02, DRB1*15:06, and DRB1*16:01. For each
allele, the top 68 scoring peptides were further divided into seven pools of approximately 10 peptides
each, to be used in the epitope screening experiments.
2.4. In Vitro Expansion of YFV-Specific T Cells
CD4+ T cells were isolated by magnetic bead negative selection (Miltenyi Biotech, Bergisch
Gladbach, Germany) and co-cultured with autologous antigen presenting cells (APCs) at a 2:1 ratio in
RPMI 1640 (Omega Scientific, Tarzana, CA) supplemented with 5% human serum (Cellgro, Lincoln,
NE,) at a concentration of 4 × 106 cells/mL in 24-well plates (BD Biosciences, San Diego, CA). Cells were
stimulated with YF-specific DRB1 pools [1 µg/mL] and additional IL-2 [10 U/mL]; eBioscience was
added every four days after the initial pool-stimulation, as previously described [34]. After 14 days of
in vitro expansion, the IFNγ response against individual peptides was evaluated by ELISPOT assay.
2.5. Ex Vivo IFNγ ELISPOT Assay
PBMCs (2 × 105 cells/well) were incubated in triplicates with 2 µg/mL of HLA-matched peptides
in plates coated with the anti-human IFNγ antibody (mAb 7-B6-1; Mabtech, Stockholm, Sweden) at
37 ◦C for 20–24 h and developed as previously described [34,35]. If the rare event when the exact HLA
match was not available, we considered closely related HLA alleles within the same supertype [36].
PBMCs were first screened with peptide pools containing 10 peptides per pool and subsequently
deconvoluted to identify the individual epitopes [37].
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2.6. YFV-CD4 Megapool Design and Manufacture
To design a Megapool (MP) encompassing epitopes providing maximum coverage and breadth,
the set of epitopes experimentally defined in this study was expanded to include additional
epitopes independently identified in other studies, and predicted promiscuous epitopes as previously
reported [35,38]. First, we queried the IEDB (April, 2017) for previously identified YFV CD4 epitopes
using the following query parameters: Assay-Positive Assays Only; Assay-T Cell Assays (i.e., no B
Cell Assays or MHC Ligand Assays); Antigen/Organism: Yellow fever virus (ID:11089); Host-Humans;
and MHC restriction: MHC Class II. The resulting set composed of 94 epitopes was further
supplemented by additional prediction analyses. Prediction of HLA class II promiscuous binding
peptides was carried out using sequences from the YF-17D vaccine strain and virus isolates derived
from a recent Brazilian outbreak (protein ID: ARM37843.1) [39] by using the “7-allele-method” [40]
embedded in the Tepitool tool [41], considering peptides with a median consensus percentile cutoff
of ≤20. To avoid redundancy across and within the three different datasets, epitopes were clustered
using the IEDB cluster 2.0 tool [42] applying the clique clustering method and 70% homology criteria.
Overall, the experimentally defined YFV epitopes of this study (n = 129) were combined with the IEDB
derived epitopes (n = 94) and the ones retrieved from the prediction (n = 292) for a CD4 YFV-MP
containing, after clustering, a total of 275 peptides (Table S3). These 275 peptides were synthesized,
and an epitope MP was derived as previously described by sequential lyophilization. The resulting
MP lyocake was resuspended in DMSO to a concentration of 2 mg/mL of each individual peptide as
previously described [38].
2.7. Flow Cytometry
The following conjugated Abs were used in the present study: CD3-Alexa Fluor 700 (OKT3),
CD8-BV650 (RPA-T8) (Biolegend, San Diego, CA, USA), CD4-APC-efluor 780 (RPA-T4), IFNγ-FITC
(4S.B3) (Thermo Fisher Scientific, Waltham, MA, USA), CD14-V500 (M5E2), and CD19-V500 (HIB19) (BD
Biosciences; San Jose, CA, USA). For the exclusion of dead cells, the Fixable Viability Dye eFluor™ 506
(LIVE/DEAD) was used (Thermo Fisher Scientific). To identify the IFNγ production on antigen-specific
CD4+ T cells, one million of PBMCs were cultured with CD4+ YFV-MP (1 µg/mL), Dimethyl sulfoxide
(DMSO) (1%) as a negative control, and Phorbol 12-Myristate 13-Acetate (PMA) (0.1 µg/mL) and
ionomycin (1 µg/mL) as a positive control in the presence of brefeldin A (1 µg/mL) (BD Biosciences) for
6 h and subsequently permeabilized and stained as described previously [35]. Cells from donors have
been excluded from the analysis if the IFNγ response to PMA and ionomycin stimulation was lower
than 1% in the CD3+ cells. Cells were acquired on an LSR-II flow cytometer (BD Biosciences), and the
analysis was performed using FlowJo 10.5.3. software (BD Biosciences).
2.8. Statistical Analysis
All statistical analyses were performed using the Wilcoxon-rank test. The test was two-tailed, and
statistical significance was achieved at p < 0.05. GraphPad Prism 8.0 software (San Diego, CA, USA)
was used for statistical analyses.
3. Results
3.1. Selection of a Panel of DRB1 Alleles that Affords High Population Coverage
Our goal was to identify a comprehensive set of Yellow Fever epitopes by assessing the CD4+
T cell response in a cohort of vaccinated donors with YF-VAX®. Table S1 lists the gender, age,
months post-vaccination, and HLA typing for each donor. To ensure that our donor cohort was
representative of the general population, we compared frequencies of the main HLA class II alleles
observed in our donor cohort with those observed in our repository of over 3500 donors, reflecting a
variety of clinical studies and a diverse set of ethnicities, ranging from the USA, South and Central
America, Asia, South Africa, and Europe (Figure S1A).
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In general, the HLA representation was similar in the different populations. Of the eleven different
HLA class II alleles identified in our cohort with phenotypic frequencies >5%, seven (64%) are also
present in the general population with frequencies >5%. At the same time, nine (82%) of the eleven
DRB1 alleles included in a reference panel of the most common and representative class II alleles in the
general population [43] are also present in the cohort studied here. The three most common DRB1
alleles in the cohort (DRB1*04:01, DRB1*13:01, and DRB1*15:01), present with frequencies of 15% or
greater, are also found in the worldwide population with frequencies >5%.
Next, we selected for our experiments a panel of seventeen different DRB1 alleles (see methods
for list) based on their being represented in the donor cohort, and also being reasonably frequent
worldwide. Figure S1B shows that the seventeen HLA-DRB1 alleles selected allow coverage of both
alleles in 65% of the individuals from the donor cohort from Table S1, and for one allele in the remaining
35%; all donors are represented by at least one allele in the prediction panel. The same analysis with
the general repository of over 3500 donors, reflecting a variety of clinical studies and a diverse set
of ethnicities, ranging from the USA, South and Central America, Asia, South Africa, and Europe,
found similar representation by the panel, with 51% of individuals covered for both alleles, and 38%
by one; only 11% were not covered at all.
3.2. Identification of Yellow Fever Epitopes
A total of 681 fifteen-mer peptides overlapping by 10 residues spanning the entirety of the YF-17D
polyproteins were synthesized. Next, the Analysis Resource from IEDB was used to predict the
capacity of these 681 peptides to bind the selected HLA-DRB1 alleles. Sets of the top 10% binders
(corresponding to 68 peptides) were then selected for each allele, and tested in donors expressing the
matching HLA-DRB1 variant.
Each of the peptide sets was screened in 1–8 (average 2.8) HLA-matched donors. If the rare event
when the exact HLA match was not available, we considered closely related HLA alleles within the same
supertype [36]. A total of 215 epitopes, representing 129 unique epitope sequences, were identified;
69 of these are described here for the first time. The top 40 epitopes, which account for 75% of the total
response, are listed in Table 1, which also shows the number of responding donors, and putative HLA
restriction; overall, 90% of the total response can be attributed to the top 70 epitopes. Table S4 shows a
complete listing of all peptides identified, including response frequency and HLA restriction.
Table 1. Most dominant peptides are recognized by YF-17D vaccinees. PBMCs, peripheral blood
mononuclear cells.
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Table 1. Cont.









ILAECARRRLRTLVL NS3 1696 4983 17.5 1 DRB1*16:02
VVVLNRKTFEREYPT NS3 1871 4873 21.0 2 DRB1*11:04,DRB1*13:01





GEVIGLYGNGILVGD NS3 1631 3757 27.1 2 DRB1*15:01,DRB1*15:02
RFLPQILAECARRRL NS3 1691 3480 29.7 2 DRB1*04:07,DRB1*10:01










KAGKSVVVLNRKTFE NS3 1866 2773 35.8 2 DRB1*11:04,DRB1*13:01









NNGGDAMYMALIAAF NS2A 1196 2523 41.5 1 DRB1*13:01
ITAHLKRLWKMLDPR C 61 2400 43.2 2 DRB1*11:01,DRB1*11:04




GSIVACAKFTCAKSM E 396 2353 46.7 2 DRB1*11:04,DRB1*13:01
NNLYKLHGGHVSCRV E 556 2287 48.4 1 DRB1*01:01
LLIGFGLRTLWSPRE NS2A 1216 2233 50.0 2 DRB1*13:01,DRB1*15:01






VVVQDPKNVYQRGTH NS1 866 2123 53.2 2 DRB1*03:01,DRB1*13:01
RVVASLMRGLSSRKR C 86 2087 54.7 2 DRB1*04:03,DRB1*13:01
GNTSLLWNGPMAVSM NS4B 2466 2027 56.2 1 DRB1*01:01
KIERWFVRNPFFAVT M 241 1960 57.6 2 DRB1*15:02,DRB1*16:02
EVDISVVVQDPKNVY NS1 861 1957 59.0 1 DRB1*13:01
FVGVMYNLWKMKTGR NS4B 2491 1900 60.4 2 DRB1*11:01,DRB1*11:04
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GTRKIMKVVNRWLFR NS5 2876 1720 63.0 1 DRB1*15:01
DGDSYYYSEPTSENN NS3 1956 1610 64.2 1 DRB1*04:01
PKNVYQRGTHPFSRI NS1 871 1600 65.3 1 DRB1*16:02
FLFNILTGKKITAHL C 51 1573 66.5 2 DRB1*01:01,DRB1*11:01














GVIMMFLSLGVGADQ E 766 1313 70.6 2 DRB1*11:01,DRB1*15:01
QYVIRAQLHVGAKQE E 421 1270 71.5 1 DRB1*16:02




HATLTYRMLEPTRVV NS3 1751 1213 73.3 2 DRB1*01:01,DRB1*10:01
RWLFRHLAREKNPRL NS5 2886 1140 74.2 1 DRB1*13:01




3.3. CD4+ T Cells Recognize both Structural and Non-Structural Proteins
Epitopes were derived from all three structural proteins, as well as the seven non-structural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The structural proteins C and E, as well
as the non-structural proteins NS3 and NS5, were the most dominantly targeted CD4 antigens and
accounted for 25, 31, 43, and 45 of the 215 total epitopes, respectively (Figure 1A).
Next, we evaluated if antigen size affects the CD4 targeting preference. While there is a correlation
between the size and percent of CD4 epitopes identified for M, E, NS2A, NS3, NS4, a clear exception is
represented by the dominance of the C antigen, which is more immunogenic than size alone would
predict (Figure 1B). When the magnitude of response was evaluated, C, E, NS3, and NS5 were the
most immunogenic antigens, accounting for 15, 12, 29, and 20% of the total magnitude of response,
respectively. In total, 30% of the response was associated with structural proteins and 70% with
non-structural proteins (Figure 1C).
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Figure 1. Protein location and magnitude of response of CD4+ epitopes identified. (A) Patterns
of protein immunodominance of CD4+ T cells responses against yellow fever virus (YFV) epitopes.
The fraction of identified epitopes is plotted as a function of the protein they are derived from (capsid
protein [C], membrane protein [M], envelope protein [E], non-structural protein 1 [NS1], NS2A, NS2B,
NS3, NS4A, NS4B, and NS5). Numbers represent the number of epitopes identified. (B) Relative
distribution of epitopes derived from the structural (C, M, and E) or NS proteins (NS1–5). The gray
bars reflect a relative number of peptides for each protein predicted to bind the various HLA-DR
molecules, and the white bars show the percentage of all possible peptides (percentage of the YF-17D
polyproteins) accounted for by each antigen. (C) The magnitude of response per structural (C, M,
and E) or NS proteins (NS1–5). The magnitude of response was defined as the average sum total of
spot-forming cells (SFCs)/donor associated with each protein. Percentages in the upper right corner
reflect the relative response directed at either structural or NS protein responses.
3.4. Magnitude of Responses Varies as a Function of HLA
The overall immunoreactivity as a function of the different HLA-DRB1 allelic peptide sets and
different proteins is shown in Table 2. The average magnitude of responses for each allele (total
magnitude of responses detected for that allele corrected for the number of donors tested) was
2928 ± 2485.9 IFNγ SFCs/106 PBMCs, and the average number of epitopes recognized per donor in
the context of each allele was 5 ± 3 epitopes/donor. In particular, certain alleles, such as DRB1*16:02,
DRB1*13:01, DRB1*11:04, and DRB1*01:01 were associated with a relatively high magnitude of
response (>4600 SFCs), while DRB1*10:01, DRB1*15:02, DRB1*08:02, DRB1*04:07, and DRB1*04:01
were associated a moderate magnitude of response (>2280 SFCs). Other alleles, such as DRB1*04:03,
DRB1*15:01, DRB1*11:01, DRB1*07:01, DRB1*03:01, DRB1*15:06, and DRB1*12:01 were associated with
relatively weak magnitudes of response (<2280 SFCs) and accounted for less than 17% of the total
response when combined.
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Epitopes/Donor C M E NS1 NS2A NS2B NS3 NS4A NS4B NS5
01:01 3 4644 8.3 820 140 876 0 300 171 831 0 988 519
03:01 2 850 4.5 0 0 93 200 0 0 413 0 47 97
04:01 5 2280 4.6 179 0 297 0 0 64 1211 116 213 199
04:03 3 2093 3.3 1307 0 38 0 160 0 98 0 322 169
04:05 1 0 0.0 0 0 0 0 0 0 0 0 0 0
04:07 3 2577 4.3 0 0 647 0 51 0 1080 164 351 283
07:01 3 984 1.7 29 0 76 0 0 0 180 0 0 700
08:02 1 2993 6.0 1320 87 0 0 0 0 320 0 0 1267
10:01 1 4560 13.0 0 0 833 0 300 0 2253 0 793 380
11:01 4 1642 4.8 180 0 313 0 0 58 125 38 73 854
11:04 3 5185 5.8 1625 0 747 0 0 0 493 0 672 1648
12:01 2 577 1.5 0 0 70 0 0 0 80 0 0 427
13:01 5 5746 5.6 889 453 314 784 1023 0 1604 0 0 678
15:01 8 1767 2.1 391 72 93 0 240 0 556 108 16 292
15:02 2 3105 6.5 57 893 0 0 0 0 182 237 182 1555
15:06 1 820 2.0 0 0 0 0 0 0 0 0 250 570
16:02 1 9950 10.0 573 320 1450 1600 290 0 5097 0 140 480
TOTAL 48 49,773 - 7369 1965 5846 2584 2365 293 14,523 662 4047 10,117
% - 100 - 14.8 3.9 11.7 5.2 4.8 0.6 29.2 1.3 8.1 20.3
Mean - 2928 5 433 116 344 152 139 17 854 39 238 595
SD - 2485.9 3.3 553.9 238.6 421.6 420.0 258.4 44.5 1261.6 72.3 305.0 486.7
1 Number of HLA tested in the donor cohort included in the epitope identification studies.
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3.5. Development and Validation of a CD4+ Yellow Fever Epitope Mega Pool
To enable the detection of ex vivo CD4+ T cell response elicited by the YF-17D vaccine, we applied
a three-fold approach to develop a YFV mega pool (YFV-MP) as outlined in more detail in material
and methods. Next, we validate the YFV CD4 MP measuring the IFNγ production of antigen-specific
CD4+ T cells (Figure 2A,B). A greater percentage of antigen-specific CD4+ T cells producing IFNγ after
YFV-MP stimulation was observed than in DMSO cultured cells (Figure 2C).
Figure 2. Validation of YVF-MP in vaccine individuals. (A) Representative dot plot of the gating
strategy for CD4+ T cell selection. Lymphocytes were identified in forward scatter (FSC), and side
scatter (SSC) plots. The doublets, CD14+, and CD19+ cells were excluded. Next, gated on CD3+
cells, the CD4+ and CD8+ population was selected. (B) Representative dot plot of gating strategy
for antigen-specific CD4+ T cells producing IFNγ after DMSO or YFV-MP stimulation in the same
donor. Fifteen samples from YF-17D vaccinees were used for YFV-MP validation. (C) Comparison of
percentage of CD4+ T cells producing IFNγ between DMSO and YFV-MP stimulated cells. Data are
expressed as the median and the range. Statistical analyses were performed using a two-tailed Wilcoxon
test. p = 0.001.
4. Discussion
YFV is a mosquito-borne member of the genus flavivirus, including other important
human-pathogenic viruses genetically related, such as dengue, Japanese encephalitis, West Nile,
and Zika viruses. Out of all flavivirus, a licensed vaccine is only available against DENV, JEV,
and YFV, although they present with different efficacy profiles. For example, a safety signal in
dengue seronegative vaccine recipients has sparked some concern on the widespread application
of Dengvaxia [28], while vaccines against JEV and YFV have been administered successfully in
humans for decades [44]. The vaccine against YFV has proven to be amongst the most successful
vaccines in terms of risk factors and the induction of long-term protection for at least 10 years [45,46].
However, a current resurgence of YF in the metropolitan areas of Brazil has sparked renewed interest
in the exact phenotypes found in the general population. We have previously shown in the case
of natural infection with DENV that a variation in terms of frequency of response and magnitude
exists [47]. It is thus important to comprehensively address the CD4+ T cell response covering the
most frequently expressed HLA phenotypes in a given population. We analyzed the class II epitopes
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restricted by HLA-DRB1 alleles, a locus that worldwide has been observed to be associated with
stronger responses to flavivirus epitopes, compared to other HLA class II loci [48]. Here, it was
found that a high-to-moderate fraction of the response, in terms of magnitude, was restricted by
HLA-DRB1*16:02, HLA-DRB1*13:01, HLA-DRB1*11:04, HLA-DRB1*01:01, DRB1*10:01, DRB1*15:02,
DRB1*08:02, DRB1*04:07, and DRB1*04:01 alleles in YFV vaccinated individuals from the San Diego
area. Interestingly, these findings are related to the previous report showing that the DRB1*01:01,
DRB1*08:02, and DRB1*04:01 alleles recognize YFV epitopes in a cohort of YFV vaccinated donors
from Brazil [9]. Mechanism of vaccine protection [49]. While neutralizing antibodies against YFV have
been widely recognized as the correlate of protection against re-infection, the importance of cellular
immunity has been acknowledged [44]. Particularly, CD4+ T cells have been shown to contribute by
providing help to both CD8+ T cells and antibody-producing B cells [50].
CD4 epitopes derived from YF-17D have previously been reported [7–19]. However, most studies
have focused on a limited amount of HLA alleles that failed to address the diversity of HLA.
Identifying immunodominant epitopes in YFV vaccinees is fundamental for the characterization
of the adaptive immune response against YF [51,52]. In the present study, CD4+ T cells from YFV
vaccinated donors recognized both structural and non-structural proteins and preferably targets the C,
E, NS3, and NS5 proteins. Although few studies have identified YFV class II epitopes, a previous report
found a set of 108 immunogenic YFV peptides from the envelope and non-structural proteins in YF
vaccinated donors from Brazil (ten out of those peptides that belong to E, NS2A, NS2B, NS3, and NS4A
proteins, were included in our study) and showed that a high number of NS3 and NS5 peptides were
recognized by T cell from vaccinated donors, which is consistent with our findings [9]. In addition,
a previous report identified a strong CD4+ T cell response to epitopes derived from the C and E proteins
of YFV in a cohort of YFV vaccinated individuals [19]. Similarly, previous studies in other flavivirus
models, like Dengue and Zika, have been shown that the CD4+ T cell response targets to C, E, NS3,
and NS5 [34,35,51], suggesting that the structural proteins from capsid and envelope, as well as the
non-structural proteins NS3 and NS5, are highly immunodominant, a feature that is shared between
the flaviviruses [2]. In a parallel study, we have investigated the potential cross-reactivity of some of
the epitopes identified and found limited cross-reactivity of epitopes induced by YF17D vaccination
with other flaviviruses, such as DENV, ZIKV, and JEV [53]. The knowledge of immunodominance is
highly relevant in the context of vaccine design, particularly as chimeric flavivirus vaccines, have been
designed. Excluding proteins that are dominant T cell targets might have a direct influence on the
efficacy of such vaccine constructs.
5. Conclusions
Comprehensive epitope mapping across all ten yellow fever proteins revealed patterns of
immunodominance of YFV-specific CD4+ T cell responses that preferably target the C, E, NS3, and NS5
proteins. The subsequent development of a CD4 YFV-specific MP allows the ex vivo identification of
YFV-specific responses in small amounts of blood samples, irrespective of the HLA phenotype, which
provides a valuable tool in the evaluation of vaccine-specific CD4+ T cells.
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